News About: Pharm. Industry
Philips to strengthen home healthcare business
Royal Philips Electronics (Philips) of the Netherlands says it will reinforce its home healthcare business for active aging to help protect the health and safety of the active aging population.
Active aging is def...
Hemorrhoid on increase
The National Health Insurance Corporation (NHIC) says the number of people suffering from hemorrhoid who visited hospitals was 214,100 last year.
Last year, 205,095 people had their senile cataract treatment cover...
Government to sustain tax breaks for facility investment
The government plans to extend 7% tax reduction on pharmaceutical facility investment of pharmaceutical by 2013, while local logistics tax benefits will be also extended to 2012.
The proposed revision, subject to p...
Health ministry should let loose drugmakers
The National Assembly Research Service (NARS) said on August 23 that the Health Ministry's regulations concerning rebate provisions are impeding fair competition, demanding more flexible implementation of the current ...
Local leading drugmakers at crossroad
Prospects have been grim for Korean pharmaceutical companies, as they are getting pressed by multinationals' increasing market presence and the government's pressure to lower drug costs, such as a cash incentive plan ...
Korean drugmakers urged to benchmark Scotland’s biotechnology business
Domestic pharmaceutical companies will have to model the biotechnology business in Scotland by exchanging the required technologies for sustained growth in a global arena, according to experts.
“This is a great opp...
Hanmi targets European market with Amosartan
Hanmi Pharm said on August 23 it is conducting a phase I clinical trial of Amosartan (amlodipine camsylate+losartan potassium), a hypertension combination drug in CCB + ARB class, to obtain an approval in EU.
Compa...
Daewoong enters agreement with Medivir for markeing rights to cold sore treatment Xerclear
Daewoong Pharm says it has signed an agreement with Swenden-based Medivir AB to distribute Medivir’s Xerclear (acyclovir and hydrocortisone) for non-prescription use (OTC) in Korea.
Xerclear is the first and only t...
Handok’s Amaryl M exposed to fierce competition
A blockbuster drug in Korea will not be as stable as before with a growing number of pharmaceutical companies poising to enter a 20 billion Amaryl M (glimepiride + metroformin HCl) market.
More than 20 pharmaceuti...
Hanmi spends 15% of revenue on R&D
Details of drug company spending revealed in the first half of this year show that a combined spending of the country's top pharmaceutical companies (29 companies listed in the Korean Exchange plus 17 companies listed...
